Cargando…

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median overall survival of only about 13 months, indicating the urgent need for novel therapies. Delta-like protein 3 (DLL3) has been identified as a tumor-specific cell surface marker on neuroendocrine cancers, includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaspers, Janneke E., Khan, Jonathan F., Godfrey, William D., Lopez, Andrea V., Ciampricotti, Metamia, Rudin, Charles M., Brentjens, Renier J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145930/ https://www.ncbi.nlm.nih.gov/pubmed/36951942 http://dx.doi.org/10.1172/JCI166028

Ejemplares similares

Cytokine IL-36γ Improves CAR T Cell Functionality and Induces Endogenous Anti-Tumor Response
por: Li, Xinghuo, et al.
Publicado: (2020)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
por: Hu, Biliang, et al.
Publicado: (2017)

Multipurposing CARs: Same engine, different vehicles
por: Hossian, A.K.M. Nawshad, et al.
Publicado: (2022)

MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer
por: Caeser, Rebecca, et al.
Publicado: (2021)

Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
por: Koneru, Mythili, et al.
Publicado: (2015)

CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
por: Kuhn, Nicholas F., et al.
Publicado: (2020)

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
por: Rudin, Charles M., et al.
Publicado: (2023)

How do CARs work?: Early insights from recent clinical studies targeting CD19
por: Davila, Marco L., et al.
Publicado: (2012)

DLL3: an emerging target in small cell lung cancer
por: Owen, Dwight H., et al.
Publicado: (2019)

IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
por: Coffelt, Seth B., et al.
Publicado: (2015)

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
por: Jin, Chun-Hui, et al.
Publicado: (2018)

DLL3 regulates Notch signaling in small cell lung cancer
por: Kim, Jun W., et al.
Publicado: (2022)

Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer
por: Isobe, Yoshitaka, et al.
Publicado: (2020)

DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail
por: Furuta, Megumi, et al.
Publicado: (2019)

Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
por: Geffers, Insa, et al.
Publicado: (2007)

Context-Dependent Functional Divergence of the Notch Ligands DLL1 and DLL4 In Vivo
por: Preuße, Kristina, et al.
Publicado: (2015)

Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
por: Battram, Anthony M., et al.
Publicado: (2021)

Elevated DLL3 in stomach cancer by tumor-associated macrophages enhances cancer-cell proliferation and cytokine secretion of macrophages
por: Ye, Jian-Bin, et al.
Publicado: (2021)

Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine
por: Shimizu, Hiromichi, et al.
Publicado: (2014)

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
por: Pang, Nengzhi, et al.
Publicado: (2021)

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
por: Zhou, Ting, et al.
Publicado: (2020)

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18
por: Glienke, Wolfgang, et al.
Publicado: (2022)

Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
por: Li, Fanfan, et al.
Publicado: (2022)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19
por: Lu, Ting, et al.
Publicado: (2022)

Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
por: Sharma, Sai Kiran, et al.
Publicado: (2021)

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages
por: Kersten, Kelly, et al.
Publicado: (2017)

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
por: Zhou, Wenping, et al.
Publicado: (2023)

Normal Development in Mice Over-Expressing the Intracellular Domain of DLL1 Argues against Reverse Signaling by DLL1 In Vivo
por: Redeker, Christian, et al.
Publicado: (2013)

The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro
por: Tveriakhina, Lena, et al.
Publicado: (2018)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Low Toxicity and Favorable Overall Survival in Relapsed/Refractory B-ALL following CAR T cells and CD34-selected T Cell Depleted Allogeneic Hematopoietic Cell Transplant.
por: Fabrizio, Vanessa A., et al.
Publicado: (2020)

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
por: Rafiq, Sarwish, et al.
Publicado: (2018)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

Interaction with Mesenchymal Stem Cells Provokes Natural Killer Cells for Enhanced IL-12/IL-18-Induced Interferon-Gamma Secretion
por: Thomas, Heike, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rrpta901e00kliclfotp0savki